Key facts
- Notable investors include Lanchi Ventures, YuanBio Venture Capital, Suzhou Angel Fund of Funds, Laurel Venture Capital, Zhongqi Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for SiranBio
- ·The full record, as it builds
Funding rounds
No funding rounds for SiranBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SiranBio
Developer of innovative drugs designed for the nucleic acid therapy field. The company offers single-target and dual-target nucleic acid drug technology platforms and extrahepatic delivery platforms, and it has rapidly developed a pipeline of small nucleic acid drugs for intrahepatic and extrahepatic FIC and BIC, including antiviral, cardiovascular and metabolic diseases, autoimmunity, central nervous system, and other related diseases, thereby providing customers with reliable and innovative products.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Website
- siranbio.com/
- Ownership
- Privately Held (backing)
SiranBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SiranBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SiranBio in its N-PORT filings yet. We sweep new filings monthly.